Caixin Global – Latest China News & Headlines

Home >


CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

JD Logistics Takes Pitches from Banks for Planned Hong Kong IPO in 2021
New Rules Derail Mega Livestreaming E-Commerce Deal
Trending in China: Why Are People Queuing Eight Hours and Paying $30 for a Cup of Milk Tea?
Trending in China: Teacher Assaulting Children Raises Question About Role of Volunteers in Education
‘Look, No Hands!’ - AutoX Rolls Out China’s First Self-Driving Fleet Without Safety Drivers
U.S. Firms Deny Selling to China Military, as Washington Prepares New Blacklist
Baker Bros. Advisors Sells ADSs in BeiGene Just Months After Buying Shares
Trending in China: Sharing Students’ Grades Online – The Fine Line Between Motivation and Public Shaming
Tesla Rival Li Auto Plans New Share Sale to Bankroll R&D
Alibaba Logistics Arm Chills with Ethiopian Airlines to Transport Covid-19 Vaccines
U.S. Blacklist of Chinese Tech Firms Continues to Grow
China's Bluetooth Audio Chip King Set For $741m Shanghai IPO
U.S.-Blacklisted Hikvision Zooms in on COVID Tracking Demand Reports First Quarterly Profit of 2020 as Travel Recovers
Xiaomi Raises Nearly $4 Billion Through Sale of Shares and Bonds
Baidu Leads China in AI Patent Applications and Ownership
Trending in China: Now Forbidden on China’s Trains
Chinese Biopharma Firm Pegbio Nets $122m in Pre-IPO Round From YF Capital, Yingke, Others
NEV Makers Nio and Xpeng Keep Revving Up Sales, But Investor Unimpressed
Britain Bans Installation of New Huawei 5G Equipment from September 2021 in Major U-Turn
SBCVC-Backed Dingdang Kuaiyao Nets $150m in Series B+ Round

By DealStreetAsia / Oct 21, 2020 05:49 PM / Finance

SoftBank China Capital (SBCVC)-backed Chinese online-to-offline medicine platform Dingdang Medicine Express (Beijing) Technology Co., Ltd, also known as Dingdang Kuaiyao, has secured 1 billion yuan ($150 million) in a Series B+ round of financing, according to a company statement on Tuesday.

Chinese insurance and financial service provider Taikang Insurance Group, Haier Biomedical and Longmen Investment were the three new investors joining the round.

Existing investors who re-upped in the round were SBCVC, China Merchants Bank’s CMB International Corporation Limited, and Sinopharm-CICC, a healthcare-based joint fund co-launched by state-owned Sinopharm Group and CICC Capital in 2016.

China Renaissance acted as the financial advisor for the transaction.

Prior to the latest round, Dingdang raised an undisclosed sum from state-owned HuNan Hi-Tech Investment Group and Beijing-based asset management player Skycus Capital earlier in August 2020.

In 2019, SBCVC had led a $90-million Series B round funding in Dingdang Kuaiyao with the participation of Sinopharm-CICC, CMB International and CICC Qizhi. In 2018, SBCVC had exclusively invested $45 million in Dingdang Kuaiyao.

The company will deploy the latest proceeds towards market expansion, product and service innovation, as well as business ecosystem advancement.

Set up in 2014, Dingdang is a mobile-friendly, drug-selling platform that aims to door-deliver drugs within 28 minutes. It operates in 10 provinces and cities in Beijing, Shanghai, Guangdong, among others.

The platform also offers online medical consultation services since 2018. “Dingdong has operated thousands of physical stores across Beijing, Shanghai, Guangzhou, Shenzhen, Chengdu, Tianjin, Nanjing, Hangzhou and Wuhan,” said Xiaowei Ni, CEO, Haier Biomedical, in the statement.

Zhuhai Dingdang Sihao Investment is the largest shareholder in Dingdang Kuaiyao with a 21.89 per cent stake, while founder and CEO Wenlong Yang owns 14.16 per cent. Its major shareholders include SBCVC (8.53%), CMB International (7.47%), Tong Dao Capital (6.84%) and CICC Qizhi (2.82%).

Contact editor Marcus Ryder (

Related: ByteDance Gets Into Online Health With Acquisition of Medical Encyclopedia Site

Share this article
Open WeChat and scan the QR code